Herclon 150Mg Inj contains Trastuzumab, which is used for treating patients with HER2-positive breast cancer and HER2-positive metastatic gastroesophageal adenocarcinoma. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of programmed cell death.

FAQs

How does Herclon 150Mg Inj work?

Herclon 150Mg Inj contains Trastuzumab, which works by inhibiting the excess production of a protein called human epidermal growth factor receptor 2 (HER2) in mammalian cells. This causes inhibition of the cancer cell growth.

What are the points to be informed to the doctor before starting treatment?

Inform your doctor whether you have received any other cancer treatment. Herclon 150Mg Inj may cause a decrease in left ventricular ejection fraction, cardiomyopathy, hypersensitivity reactions, pulmonary toxicity, and embryo-fetal toxicity during the treatment. Hence, inform your oncologist if you have any cardiovascular conditions, liver/kidney disease, lung problems, are pregnant, are planning to become pregnant, or are breastfeeding before receiving Herclon 150Mg Inj.